Last reviewed · How we verify
NATACYN®
At a glance
| Generic name | NATACYN® |
|---|---|
| Also known as | Active Comparator Arm |
| Sponsor | IVIEW Therapeutics Inc. |
| Drug class | Polyene Antimicrobial |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
- Fungal Blepharitis
- Fungal conjunctivitis
- Fungal keratitis
Common side effects
- Eye irritation
- Eye discomfort
- Eye hyperemia
- Eye pain
- Tearing
- Foreign body sensation
- Eye edema
- Change in vision
- Allergic reaction
Serious adverse events
- Corneal opacity
- Dyspnea
- Chest pain
- Paresthesia
Key clinical trials
- Rose Bengal Electromagnetic Activation With Green Light for Infection Reduction (PHASE3)
- Trial to Evaluate the Efficacy And Safety of IVIEW-1201 In the Treatment of Fungal Keratitis (PHASE2)
- Fungal Ulcer Treatment Augmented With Natamycin and Cyclosporine A (PHASE3)
- Mycotic Antimicrobial Localized Injection for Treatment of Corneal Ulcers (PHASE3)
- Cross-linking for Corneal Ulcers Treatment Trial (PHASE3)
- Efficacy and Safety of Natamycin and Lactulose Vaginal Suppositories in Treatment of Vulvovaginal Candidiasis (PHASE3)
- The Antibiogram and Outcomes of Antimicrobial Regimens in Microbial Keratitis: A Prospective Cohort Study
- The Mycotic Ulcer Treatment Trial II: A Randomized Trial Comparing Oral Voriconazole vs Placebo (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NATACYN® CI brief — competitive landscape report
- NATACYN® updates RSS · CI watch RSS
- IVIEW Therapeutics Inc. portfolio CI